

2017 10	137	68	2015 6
			69

%%)(%) (9) (9)+

ê \$

33769

%&-3ð•QðÀE6a i5æ&"0i*n nV

2

2693R 69 \$ i51+••j

Impact of Clopidogrel Combined with Ginkgo Biloba Extract Injection on Patients with Acute Cerebral Infarction AN

Sheng WANG Cui- yu

Department of Neurology, Changan Hospital, Xi' an 710016, China

Abstract Objective To investigate the impact of clopidogrel combined with ginkgo biloba extract injection on patients with acute cerebral infarction. **Methods** From June 2015 to October 2017, a total of 137 patients with acute cerebral infarction were selected in the Department of Neurology, Chang' an Hospital, and they were divided into control group (n= 68) and study group (n= 69) according to random number table. Patients in control group received clopidogrel, while patients in study

1 n %
Table 1 Comparison of clinical effect between the two groups

68	19	27.9	31	45.6	18	26.5
69	7	10.2	33	47.8	29	42.0

2 α -LDL Hcy hs-CRP
 $\bar{x} \pm s$
Table 2 Comparison of serum levels of α -LDL Hcy and hs-CRP between the two groups before and after treatment

	α -LDL μ g/dl		Hcy μ mol/L		hs-CRP ng/dl	
68	83.02 \pm 7.17	72.46 \pm 6.24	19.09 \pm 3.73	14.59 \pm 3.72	1.59 \pm 0.68	1.04 \pm 0.38
69	82.68 \pm 6.93	66.78 \pm 5.12	18.58 \pm 4.27	11.76 \pm 2.41	1.62 \pm 0.73	0.73 \pm 0.24
t	0.282	5.828	0.744	5.292	0.248	5.718
P	0.778	<0.001	0.458	<0.001	0.803	<0.001

α -LDL= Hcy= hs-CRP= C

2.3 NIHSS FMA WHOQOL-100
NIHSS FMA WHOQOL-100
P>0.05 NIHSS
FMA WHOQOL-100
P<0.05 3

3 NIHSS FMA WHOQOL-100
 $\bar{x} \pm s$
Table 3 Comparison of NIHSS score FMA score and WHOQOL-100 score between the two groups before and after treatment

	NIHSS		FMA		WHOQOL-100	
68	17.98 \pm 3.16	14.83 \pm 4.48	32.04 \pm 4.09	55.91 \pm 7.26	44.92 \pm 7.76	71.62 \pm 6.73
69	18.47 \pm 3.24	10.62 \pm 4.03	31.67 \pm 3.48	63.58 \pm 8.23	45.87 \pm 8.63	79.91 \pm 8.16
t	0.896	5.784	0.571	5.781	0.677	6.482
P	0.371	<0.001	0.569	<0.001	0.499	<0.001

NIHSS= WHOQOL-100= FMA= Fugl-Meyer

2.4 4.5% 7.4%
 $\chi^2=0.118$ P>0.05 4

4 n %
Table 4 Comparison of incidence of adverse reactions between the two groups during treatment

68	1	1.5	1	1.5	1	1.5
69	2	2.9	2	2.9	1	1.5

3

